Pharmacological inhibition of protein degradation pathways revealed that both the proteasome inhibitor MG-132, and the lysosome inhibitor bafilomycin-A1, attenuated LAPTM4B degradation (Supplementary Fig. S2J), indicating LAPTM4B undergoes dual proteasomal and lysosomal degradation in NSCLC, in line with previous study 25. This evidence concerns the gene LAPTM4B and non-small cell lung carcinoma.